Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by My Legacy Advisors LLC

My Legacy Advisors LLC lessened its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 14.5% in the third quarter, Holdings Channel reports. The firm owned 2,227 shares of the pharmaceutical company’s stock after selling 379 shares during the period. My Legacy Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $1,036,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Signaturefd LLC increased its holdings in Vertex Pharmaceuticals by 1.1% in the 3rd quarter. Signaturefd LLC now owns 5,149 shares of the pharmaceutical company’s stock valued at $2,395,000 after purchasing an additional 55 shares in the last quarter. Sequoia Financial Advisors LLC boosted its position in Vertex Pharmaceuticals by 10.3% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 12,288 shares of the pharmaceutical company’s stock valued at $5,715,000 after buying an additional 1,147 shares during the last quarter. Oakworth Capital Inc. increased its position in shares of Vertex Pharmaceuticals by 17.6% during the third quarter. Oakworth Capital Inc. now owns 167 shares of the pharmaceutical company’s stock worth $78,000 after acquiring an additional 25 shares during the last quarter. Foundations Investment Advisors LLC increased its holdings in Vertex Pharmaceuticals by 11.3% during the 3rd quarter. Foundations Investment Advisors LLC now owns 849 shares of the pharmaceutical company’s stock worth $395,000 after purchasing an additional 86 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. raised its position in shares of Vertex Pharmaceuticals by 4.5% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 576 shares of the pharmaceutical company’s stock valued at $268,000 after purchasing an additional 25 shares in the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Price Performance

VRTX traded down $2.52 during trading on Tuesday, reaching $475.57. The stock had a trading volume of 404,407 shares, compared to its average volume of 1,171,653. The stock has a 50 day moving average of $475.48 and a two-hundred day moving average of $460.75. The company has a quick ratio of 2.26, a current ratio of 2.52 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $122.72 billion, a price-to-earnings ratio of 30.82 and a beta of 0.40. Vertex Pharmaceuticals Incorporated has a 1-year low of $341.90 and a 1-year high of $510.64.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing the consensus estimate of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The business had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.66 billion. During the same quarter last year, the firm posted $3.53 earnings per share. Vertex Pharmaceuticals’s revenue was up 6.1% compared to the same quarter last year. As a group, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post -2.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Barclays cut shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $472.00 to $509.00 in a report on Monday, August 5th. Royal Bank of Canada reduced their price target on shares of Vertex Pharmaceuticals from $431.00 to $425.00 and set a “sector perform” rating on the stock in a research report on Friday, October 4th. Raymond James reissued a “market perform” rating on shares of Vertex Pharmaceuticals in a report on Thursday, October 10th. Scotiabank assumed coverage on Vertex Pharmaceuticals in a report on Wednesday, October 16th. They set a “sector perform” rating and a $480.00 target price on the stock. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a report on Friday, July 26th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, Vertex Pharmaceuticals has an average rating of “Hold” and a consensus target price of $492.92.

Insider Activity

In other news, Director Sangeeta N. Bhatia sold 646 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.00. Following the sale, the director now directly owns 4,435 shares of the company’s stock, valued at $2,217,500. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Chairman Jeffrey M. Leiden sold 3,784 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $499.00, for a total value of $1,888,216.00. Following the transaction, the chairman now owns 9,994 shares in the company, valued at approximately $4,987,006. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Sangeeta N. Bhatia sold 646 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $500.00, for a total transaction of $323,000.00. Following the completion of the sale, the director now owns 4,435 shares of the company’s stock, valued at $2,217,500. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,285 shares of company stock worth $7,101,755. Insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.